Histogen to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Business Update
SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) — Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential…
Pharmaceuticals, Biotechnology and Life Sciences
SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) — Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential…
Montrouge, France, March 3, 2022 DBV Technologies Reports Full Year 2021 Financial Results and Recent Business Updates mVP Pivotal Protocol…
– Approximately $113 Million of U.S. Product Sales in 2021 – – Approximately $13 Million of International Product Sales in…
-Top-line data readout from TERN-201 (VAP-1 inhibitor) clinical trial in NASH expected in March 2022 -Initiation of Terns’ first NASH…
NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer…
SOUTH SAN FRANCISCO, Calif., March 03, 2022 (GLOBE NEWSWIRE) — Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing…
– Quarter-end cash position of $140.2 million provides runway to complete all ongoing and planned clinical trials of milademetan, including…
Multiple data readouts expected in 2022, including updates for all three clinical programs Ends 2021 with cash position of $219.6…
Initiated the Phase 1b/2a PACIFIC Study, evaluating LP352 in participants with developmental and epileptic encephalopathies (DEEs)LP352 demonstrated statistically significant reduction…
Focus: RAD011, our investigational synthetic cannabidiol oral solutionBroad market interest in the underlying science, data, and clinical translation of the…